Amgen Inc at Leerink Global Healthcare Conference Transcript
Well, I think, we're ready to get started on behalf of Leering Partners, wanted to welcome you all to the session with Amgen so very much, my pleasure to welcome Peter Griffith, company's CFO, and actually in between, Jasper and Peter is, Casey who runs IR, Jasper Van.
Grunsven, is that how you pronounce your last name? It's very good.
My apologies. I got Jasper right, at least. So he runs, rare disease for Amgen. So I thought we'd have, Peter kick it off with some opening.
Comments. Dave, thank you, and, good morning, everyone. We're so glad to be here as we always are, here in South Beach. I have a few, prepared thoughts that I'd like to share. So we exited 2025 with strong momentum across the portfolio. 13 products delivered double-digit growth, 14 exceeded a billion dollars in annual sales, and 18 delivered record performance. That breadth supported double-digit growth in both revenue and earnings per share in 2025.
The
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
